Exenatide
EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS)
AstraZeneca · Phase 3 · Completed · Enrollment 119
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Exenatide once weekly (EQW ) | Obesity or overweight | n/r | 4 | n/r | 3.8% at week 24 |
| Dapagliflozin (DAPA) | Obesity or overweight | n/r | 4 | n/r | 1.5% at week 24 |
| EQW plus DAPA | Obesity or overweight | n/r | 4 | n/r | 6.9% at week 24 |
| Dapagliflozin plus Glucophage (MET ER) | Obesity or overweight | n/r | 4 | n/r | 1.7% at week 24 |
| Phentermine /Topiramate (PHEN/ TPM) ER | Obesity or overweight | n/r | 4 | n/r | 8.1% at week 24 |